Skip to main content
Top
Published in: Digestive Diseases and Sciences 2/2021

01-02-2021 | Hepatocellular Carcinoma | Original Article

MiR-375 Impairs the Invasive Capabilities of Hepatoma Cells by Targeting HIF1α Under Hypoxia

Authors: Chun Wang, Jie Luo, Zhihang Chen, Mingliang Ye, Yinghui Hong, Jialiang Liu, Jiayan Nie, Qiu Zhao, Ying Chang

Published in: Digestive Diseases and Sciences | Issue 2/2021

Login to get access

Abstract

Background and Aims

Hypoxia represents one of the most pervasive microenvironmental stresses in HCC due to the overwhelming growth and inadequate blood supply. HIF1α as an important transcription factor participates in the regulation of various biological behaviors of HCC cells under hypoxia. Our previous study indicated that miR-375 is a hypoxia-associated miRNA. However, the interaction between miR-375 and HIF1α remains unclear.

Methods

Bioinformatic analysis was performed for miRNA screening. qRT-PCR, western blotting, and immunohistochemical staining were used to detect the expression of related molecules. Bioinformatic analysis and dual luciferase assay were used to predict and further confirm the target association. Transwell chamber assay and flow cytometry were, respectively, used to detect migration, invasion and apoptosis of hepatoma cells.

Results

MiR-375 presented an obviously differential expression in human HCCs versus background livers (BLs) and HCCs versus normal liver tissues (NLTs). In rat models, miR-375 was gradually declined during hepatocarcinogenesis. HIF1α was remarkably upregulated at protein level rather than at mRNA level in human HCCs versus BLs, HCCs versus NLTs, BLs versus NLTs, and in rat fibrotic livers versus NLTs. HIF1α was determined to be a target of miR-375. MiR-375 inhibitor induced the migration and invasive capabilities and attenuated apoptosis of hepatoma cells under hypoxia. Depriving HIF1α by siRNA could partially reverse the function of miR-375 inhibitor under hypoxia.

Conclusions

MiR-375 impairs the invasive capabilities of HCC cells by targeting HIF1α under hypoxia.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, Eser S, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.CrossRef Ferlay J, Soerjomataram I, Dikshit R, Eser S, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.CrossRef
2.
go back to reference Kudo M, Finn RS, Qin S, Han KH, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173.CrossRef Kudo M, Finn RS, Qin S, Han KH, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173.CrossRef
3.
go back to reference Reig M, Bruix J. Lenvatinib: can a non-inferiority trial change clinical practice? Lancet. 2018;391:1123–1124.CrossRef Reig M, Bruix J. Lenvatinib: can a non-inferiority trial change clinical practice? Lancet. 2018;391:1123–1124.CrossRef
4.
go back to reference Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14:430–439.CrossRef Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14:430–439.CrossRef
5.
go back to reference Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8:705–713.CrossRef Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8:705–713.CrossRef
6.
go back to reference Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266–276.CrossRef Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266–276.CrossRef
7.
go back to reference He XX, Chang Y, Meng FY, Wang MY, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31:3357–3369.CrossRef He XX, Chang Y, Meng FY, Wang MY, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31:3357–3369.CrossRef
8.
go back to reference Chang Y, Yan W, He X, Zhang L, et al. MiR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology. 2012;143:177–187.CrossRef Chang Y, Yan W, He X, Zhang L, et al. MiR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology. 2012;143:177–187.CrossRef
9.
go back to reference Guo J, Liu X, Yang Y, Liang M, et al. MiR-375 down-regulation of the rearranged L-myc fusion and hypoxia-induced gene domain protein 1A genes and effects on Sertoli cell proliferation. Asian-Australas J Anim Sci. 2018;31:1103–1109.CrossRef Guo J, Liu X, Yang Y, Liang M, et al. MiR-375 down-regulation of the rearranged L-myc fusion and hypoxia-induced gene domain protein 1A genes and effects on Sertoli cell proliferation. Asian-Australas J Anim Sci. 2018;31:1103–1109.CrossRef
10.
go back to reference Cummins EP, Taylor CT. Hypoxia-responsive transcription factors. Pflugers Arch. 2005;450:363–371.CrossRef Cummins EP, Taylor CT. Hypoxia-responsive transcription factors. Pflugers Arch. 2005;450:363–371.CrossRef
11.
go back to reference Liu XW, Cai TY, Zhu H, Cao J, et al. Q6, a novel hypoxia-targeted drug, regulates hypoxia-inducible factor signaling via an autophagy-dependent mechanism in hepatocellular carcinoma. Autophagy. 2014;10:111–122.CrossRef Liu XW, Cai TY, Zhu H, Cao J, et al. Q6, a novel hypoxia-targeted drug, regulates hypoxia-inducible factor signaling via an autophagy-dependent mechanism in hepatocellular carcinoma. Autophagy. 2014;10:111–122.CrossRef
12.
go back to reference Rapino F, Delaunay S, Rambow F, Zhou Z, et al. Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature. 2018;558:605–609.CrossRef Rapino F, Delaunay S, Rambow F, Zhou Z, et al. Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature. 2018;558:605–609.CrossRef
13.
go back to reference Knodell RG, Ishak KG, Black WC, Chen TS, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431–435.CrossRef Knodell RG, Ishak KG, Black WC, Chen TS, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431–435.CrossRef
14.
go back to reference Wilson GK, Tennant DA, McKeating JA. Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. J Hepatol. 2014;61:1397–1406.CrossRef Wilson GK, Tennant DA, McKeating JA. Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. J Hepatol. 2014;61:1397–1406.CrossRef
15.
go back to reference Baek D, Villen J, Shin C, et al. The impact of microRNAs on protein output. Nature. 2008;455:64–71.CrossRef Baek D, Villen J, Shin C, et al. The impact of microRNAs on protein output. Nature. 2008;455:64–71.CrossRef
16.
go back to reference Pirola CJ, Fernandez GT, Castano GO, Mallardi P, et al. Circulating microRNA signature in nonalcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64:800–812.CrossRef Pirola CJ, Fernandez GT, Castano GO, Mallardi P, et al. Circulating microRNA signature in nonalcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64:800–812.CrossRef
17.
go back to reference Wen Y, Han J, Chen J, Dong J, et al. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int J Cancer. 2015;137:1679–1690.CrossRef Wen Y, Han J, Chen J, Dong J, et al. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int J Cancer. 2015;137:1679–1690.CrossRef
18.
go back to reference Lu XX, Chen YT, Feng B, Mao XB, Yu B, Chu XY. Expression and clinical significance of CD73 and hypoxia-inducible factor-1alpha in gastric carcinoma. World J Gastroenterol. 2013;19:1912–1918.CrossRef Lu XX, Chen YT, Feng B, Mao XB, Yu B, Chu XY. Expression and clinical significance of CD73 and hypoxia-inducible factor-1alpha in gastric carcinoma. World J Gastroenterol. 2013;19:1912–1918.CrossRef
19.
go back to reference Campbell EJ, Dachs GU, Morrin HR, et al. Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels. BMC Cancer. 2019;19:307.CrossRef Campbell EJ, Dachs GU, Morrin HR, et al. Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels. BMC Cancer. 2019;19:307.CrossRef
20.
go back to reference Cao D, Hou M, Guan YS, et al. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer. 2009;9:432.CrossRef Cao D, Hou M, Guan YS, et al. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer. 2009;9:432.CrossRef
21.
go back to reference Tuomisto A, Garcia-Solano J, Sirnio P, Vayrynen J, et al. HIF-1alpha expression and high microvessel density are characteristic features in serrated colorectal cancer. Virchows Arch. 2016;469:395–404.CrossRef Tuomisto A, Garcia-Solano J, Sirnio P, Vayrynen J, et al. HIF-1alpha expression and high microvessel density are characteristic features in serrated colorectal cancer. Virchows Arch. 2016;469:395–404.CrossRef
22.
go back to reference Osako Y, Seki N, Kita Y, Yonemori K, et al. Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma. Int J Oncol. 2016;49:2255–2264.CrossRef Osako Y, Seki N, Kita Y, Yonemori K, et al. Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma. Int J Oncol. 2016;49:2255–2264.CrossRef
23.
go back to reference Kong KL, Kwong DL, Chan TH, Law SY, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 2012;61:33–42.CrossRef Kong KL, Kwong DL, Chan TH, Law SY, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 2012;61:33–42.CrossRef
24.
go back to reference Cui F, Wang S, Lao I, Zhou C, et al. MiR-375 inhibits the invasion and metastasis of colorectal cancer via targeting SP1 and regulating EMT-associated genes. Oncol Rep. 2016;36:487–493.CrossRef Cui F, Wang S, Lao I, Zhou C, et al. MiR-375 inhibits the invasion and metastasis of colorectal cancer via targeting SP1 and regulating EMT-associated genes. Oncol Rep. 2016;36:487–493.CrossRef
25.
go back to reference Zhao JF, Zhao Q, Hu H, Liao JZ, et al. The ASH1-miR-375-YWHAZ signaling axis regulates tumor properties in hepatocellular carcinoma. Mol Ther Nucleic Acids. 2018;11:538–553.CrossRef Zhao JF, Zhao Q, Hu H, Liao JZ, et al. The ASH1-miR-375-YWHAZ signaling axis regulates tumor properties in hepatocellular carcinoma. Mol Ther Nucleic Acids. 2018;11:538–553.CrossRef
26.
go back to reference Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016;352:175–180.CrossRef Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016;352:175–180.CrossRef
27.
go back to reference Liu AM, Poon RT, Luk JM. MicroRNA-375 targets hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 2010;394:623–627.CrossRef Liu AM, Poon RT, Luk JM. MicroRNA-375 targets hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 2010;394:623–627.CrossRef
28.
go back to reference Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721–732.CrossRef Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721–732.CrossRef
29.
go back to reference Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9:775–789.CrossRef Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9:775–789.CrossRef
30.
go back to reference Wang W, Li X, Wang Z, Zhang J, et al. A novel “mosaic-type” nanoparticle for selective drug release targeting hypoxic cancer cells. Nanoscale. 2019;11:2211–2222.CrossRef Wang W, Li X, Wang Z, Zhang J, et al. A novel “mosaic-type” nanoparticle for selective drug release targeting hypoxic cancer cells. Nanoscale. 2019;11:2211–2222.CrossRef
Metadata
Title
MiR-375 Impairs the Invasive Capabilities of Hepatoma Cells by Targeting HIF1α Under Hypoxia
Authors
Chun Wang
Jie Luo
Zhihang Chen
Mingliang Ye
Yinghui Hong
Jialiang Liu
Jiayan Nie
Qiu Zhao
Ying Chang
Publication date
01-02-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2021
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06202-9

Other articles of this Issue 2/2021

Digestive Diseases and Sciences 2/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine